Veracyte (VCYT) Other Operating Expenses (2012 - 2026)

Veracyte has disclosed Other Operating Expenses across 15 years of filings, most recently posting $28.7 million for Q2 2026.

• In Q2 2026, Other Operating Expenses fell 23.28% year-over-year to $28.7 million; the TTM figure through Jun 2026 stood at $94.4 million (down 2.86% YoY), while the FY2025 annual figure was $93.8 million, up 23.5% from the prior year.
• Other Operating Expenses came in at $28.7 million for Q2 2026 at Veracyte, up from $27.7 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $51.2 million in Q4 2023 to a low of -$77.5 million in Q4 2022.
• Average Other Operating Expenses over 5 years is $23.8 million, with a median of $25.3 million recorded in 2024.
• Year-over-year, Other Operating Expenses sank 300.67% in 2022 and jumped 166.14% in 2023.
• Over 5 years, Other Operating Expenses stood at -$77.5 million in 2022, then jumped by 166.14% to $51.2 million in 2023, then slumped by 55.42% to $22.8 million in 2024, then retreated by 6.0% to $21.5 million in 2025, then soared by 33.59% to $28.7 million in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $28.7 million in Q2 2026, $27.7 million in Q1 2026, and $21.5 million in Q4 2025.